Objectives To evaluate the efficacy and safety of tolvaptan in the treatment of hyponatremia in patients with chronic heart failure.
Methods Screening enrolled 16 patients with chronic heart failure (≥18y), and they were randomly divided into 2 group, control group (8 cases) and treatment group (8 cases). We collected the relevant history, biochemical indicators, weight, height, general vital signs (blood pressure, heart rate and body temperature), 24-hour urine volume, heart function, rating, and Minnesota quality of life score. Serum sodium after 8 h, Serum sodium, urine volume and weight after 1d and Minnesota quality of life score after 8d, therapeutic efficacy and safety of 2 groups were evaluated.
Results The increase of serum sodium after 8 h and 1d of the treatment group was significantly higher than control group (P = 0.001). There is no difference of the increase of urine volume and the decrease of weight between 2 groups (P > 0.05), but the urine volume of treatment group has an increasing after 1d (P = 0.01), There is no difference of Minnesota quality of life score after 8d between 2 groups (P > 0.05), but the score of 2 group had significant improvements after 8d (P = 0.001). No adverse events, 1 cases of treatment group got dry mouth.
Conclusions Tolvaptan is efficacy, safety and tolerability to be used to treat Chronic heart failure patients with hyponatremia.